ExCellThera announces new data to be presented at the EBMT 2022 annual meeting MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...

ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...